Integer Holdings Co. (NYSE:ITGR) Shares Bought by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. increased its position in Integer Holdings Co. (NYSE:ITGR) by 14.7% during the third quarter, HoldingsChannel.com reports. The fund owned 2,899 shares of the medical equipment provider’s stock after acquiring an additional 372 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Integer were worth $377,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Driehaus Capital Management LLC grew its stake in Integer by 62.5% in the 2nd quarter. Driehaus Capital Management LLC now owns 353,052 shares of the medical equipment provider’s stock valued at $40,880,000 after acquiring an additional 135,750 shares during the last quarter. F M Investments LLC acquired a new position in shares of Integer during the 2nd quarter worth approximately $11,143,000. Point72 Europe London LLP purchased a new stake in Integer in the 2nd quarter valued at approximately $6,241,000. Earnest Partners LLC grew its holdings in Integer by 3.2% during the 2nd quarter. Earnest Partners LLC now owns 1,208,319 shares of the medical equipment provider’s stock valued at $139,911,000 after buying an additional 37,340 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in Integer by 0.6% during the first quarter. Vanguard Group Inc. now owns 3,826,088 shares of the medical equipment provider’s stock worth $446,428,000 after buying an additional 23,382 shares in the last quarter. 99.29% of the stock is owned by hedge funds and other institutional investors.

Integer Stock Down 1.2 %

Shares of Integer stock opened at $133.18 on Monday. Integer Holdings Co. has a twelve month low of $84.75 and a twelve month high of $140.91. The stock has a market capitalization of $4.47 billion, a price-to-earnings ratio of 41.10, a PEG ratio of 1.91 and a beta of 1.09. The company has a current ratio of 3.28, a quick ratio of 2.09 and a debt-to-equity ratio of 0.67. The business’s 50 day simple moving average is $129.20 and its 200-day simple moving average is $122.66.

Integer (NYSE:ITGR) last posted its earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 EPS for the quarter, topping the consensus estimate of $1.36 by $0.07. Integer had a net margin of 6.70% and a return on equity of 11.63%. The firm had revenue of $431.42 million during the quarter, compared to analysts’ expectations of $440.59 million. During the same quarter in the prior year, the firm earned $1.27 EPS. Integer’s quarterly revenue was up 8.7% on a year-over-year basis. Equities research analysts forecast that Integer Holdings Co. will post 5.34 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ITGR. Citigroup increased their price objective on Integer from $124.00 to $130.00 and gave the company a “neutral” rating in a research note on Tuesday, October 1st. Piper Sandler reiterated an “overweight” rating and set a $140.00 price target (up from $125.00) on shares of Integer in a report on Friday, October 25th. Truist Financial cut their price objective on shares of Integer from $150.00 to $147.00 and set a “buy” rating for the company in a research report on Friday, October 25th. KeyCorp raised their target price on shares of Integer from $139.00 to $144.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 15th. Finally, Bank of America increased their price target on Integer from $135.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $139.75.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.